Amneal director sells 34,819 shares in market

Amneal Pharmaceuticals director Deborah M. Autor reported an open-market sale of Class A Common Stock.

Rhea-AI Filing Summary

Amneal Pharmaceuticals director Deborah M. Autor reported an open-market sale of Class A Common Stock. On May 11, 2026, she sold 34,819 shares at a weighted average price of $12.94 per share in multiple trades between $12.75 and $13.27. Following the sale, she directly holds 93,660 shares.

Insider Trade Summary

Net Seller: 34,819 shares

Net Sell 1 txn

Insider Autor Deborah M.

Role Director

Sold 34,819 shs ($451K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	34,819	$12.94	$451K

Holdings After Transaction: Class A Common Stock — 93,660 shares (Direct)

Footnotes (1)

1. F1. The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 to $13.27 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 34,819 shares Weighted average sale price: $12.94 per share Price range of trades: $12.75–$13.27 per share +1 more

4 metrics

Shares sold 34,819 shares Open-market sale of Class A Common Stock on May 11, 2026

Weighted average sale price $12.94 per share Average price for 34,819 shares sold

Price range of trades $12.75–$13.27 per share Range of individual sale prices in multiple transactions

Shares held after transaction 93,660 shares Direct ownership following the reported sale

Key Terms

open-market sale, weighted average price, Class A Common Stock, Form 4

4 terms

open-market sale financial

"transaction_action: "open-market sale" for the Class A Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average price financial

"The price included in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Class A Common Stock financial

"security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transaction did Amneal Pharmaceuticals (AMRX) report for Deborah M. Autor?

Amneal Pharmaceuticals reported that director Deborah M. Autor conducted an open-market sale of 34,819 shares of Class A Common Stock. The transaction was recorded as a sale under code S, indicating a standard market disposition of shares.

At what price did Deborah M. Autor sell Amneal (AMRX) shares?

The filing shows a weighted average price of $12.94 per share for the 34,819 shares sold. A footnote explains the trades occurred in multiple transactions at prices ranging from $12.75 to $13.27 per share, inclusive.

How many Amneal (AMRX) shares does Deborah M. Autor hold after the reported sale?

After completing the reported open-market sale, Deborah M. Autor directly holds 93,660 shares of Amneal’s Class A Common Stock. This post-transaction balance is disclosed in the Form 4 as her direct ownership position following the sale.

What does the weighted average price disclosure mean in the Amneal (AMRX) Form 4?

The weighted average price of $12.94 reflects the blended price across several trades executed between $12.75 and $13.27 per share. The footnote states full trade-by-trade pricing details are available to Amneal or SEC staff upon request.

What transaction code is used for Deborah M. Autor’s Amneal (AMRX) share sale?

The transaction is reported with code S, which indicates a sale in open market or private transaction. The filing further classifies it as an open-market sale of non-derivative securities, specifically Class A Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Autor Deborah M.

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/11/2026		S		34,819	D	$12.94(1)	93,660	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 to $13.27 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)